BioSpace News Archive

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced final results from a previously completed open-label Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC).

NuGenerex Immuno-Oncology (NGIO) today announced that it has cancelled the investor conference call originally scheduled to be held, Thursday, August 27, 2020 at 9:30 am.

At the beginning of March, Pharmact launched its highly sensitive rapid antibody test BELTEST-IT COV-2. The MedTech company, which specializes in qualitative point-of-care rapid in vitro diagnostic tests, has been working for several months on the development of a new antigen test BELMONITOR COV-2: “This easy-to-use mouthwash

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the management team is scheduled to speak at the following upcoming investor conferences.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the Company will present at the Wells Fargo Securities Healthcare Conference on Thursday, September 10, 2020, beginning at 2:00 pm ET. A live and archived webcast of the event will be available from the Investor Relations page of the Company’s website at investor.seaspine.com.

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced its second quarter 2020 financial results.

ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2020, and operational and clinical development highlights

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the Shoreline RT Cervical Interbody Implant System. Shoreline RT describes a series of products that enhance NanoMetalene® technology with the Company’s proprietary Reef Topography™

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has completed enrollment in the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a second head-to-head comparative study of MAT9001 against Vascepa®

Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced its participation in the following virtual investor and industry conferences.